CRSP CRISPR Therapeutics AG
Price (delayed)
$47.91
Market cap
$4.11B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.34
Enterprise value
$4.02B
CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that
Highlights
CRSP's quick ratio is up by 26% YoY
The debt has declined by 6% year-on-year
The company's net income has shrunk by 138% YoY and by 53% QoQ
The EPS has dropped by 124% year-on-year and by 55% since the previous quarter
Key stats
What are the main financial stats of CRSP
Market
Valuations
Earnings
Shares outstanding
85.77M
Market cap
$4.11B
Enterprise value
$4.02B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.12
Price to sales (P/S)
108.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.82
Revenue
$37.31M
Gross profit
$37.31M
Operating income
-$466.57M
Net income
-$366.25M
EBIT
-$362.67M
EBITDA
-$343.41M
Free cash flow
-$144.68M
Per share
Balance sheet
Liquidity
EPS
-$4.34
EPS diluted
-$4.34
Free cash flow per share
-$1.71
Book value per share
$22.64
Revenue per share
$0.44
TBVPS
$26.58
Total assets
$2.24B
Total liabilities
$309.95M
Debt
$223.69M
Equity
$1.93B
Working capital
$1.85B
Debt to equity
0.12
Current ratio
22.07
Quick ratio
22.1
Net debt/EBITDA
0.25
Margins
Efficiency
Dividend
EBITDA margin
-920.3%
Gross margin
100%
Net margin
-981.5%
Operating margin
-1,250.4%
Return on assets
-15.8%
Return on equity
-18.5%
Return on invested capital
-18.1%
Return on capital employed
-16.8%
Return on sales
-971.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CRSP stock price
How has the CRISPR Therapeutics AG stock price performed over time
Intraday
-5%
1 week
-3.64%
1 month
15.42%
1 year
-41.86%
YTD
21.72%
QTD
21.72%
Financial performance
How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$37.31M
Gross profit
$37.31M
Operating income
-$466.57M
Net income
-$366.25M
Gross margin
100%
Net margin
-981.5%
The company's net income has shrunk by 138% YoY and by 53% QoQ
The company's operating income has shrunk by 110% YoY and by 40% QoQ
The company's gross profit has shrunk by 90% YoY and by 82% QoQ
The revenue has dropped by 90% year-on-year and by 82% since the previous quarter
Growth
What is CRISPR Therapeutics AG's growth rate over time
Valuation
What is CRISPR Therapeutics AG stock price valuation
P/E
N/A
P/B
2.12
P/S
108.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
107.82
The EPS has dropped by 124% year-on-year and by 55% since the previous quarter
The price to book (P/B) is 29% lower than the 5-year quarterly average of 3.0 and 3.6% lower than the last 4 quarters average of 2.2
The equity has increased by 2.6% YoY
The price to sales (P/S) is 185% higher than the last 4 quarters average of 38.0 but 92% lower than the 5-year quarterly average of 1302.3
The revenue has dropped by 90% year-on-year and by 82% since the previous quarter
Efficiency
How efficient is CRISPR Therapeutics AG business performance
The company's return on assets has shrunk by 126% YoY and by 53% QoQ
The ROIC has shrunk by 123% YoY and by 51% QoQ
The ROE has plunged by 120% YoY and by 52% from the previous quarter
Dividends
What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CRSP.
Financial health
How did CRISPR Therapeutics AG financials performed over time
CRSP's quick ratio is up by 26% YoY
CRISPR Therapeutics AG's current ratio has increased by 26% YoY
The debt is 88% smaller than the equity
CRSP's debt to equity is down by 8% YoY
The debt has declined by 6% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.